| Customization: | Available |
|---|---|
| Production Line: | GMP Approved |
| Transport Package: | Carton |
|
Still deciding? Get samples of US$ 1/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
1. Treat hypokalemia caused by various reasons, such as insufficient food intake, vomiting, severe diarrhea, use of potassium diuretics, periodic paralysis of hypokalemic family, long-term use of glucocorticoid and hypokalemia caused by hyperosmolar glucose.
2. Prevention of hypokalemia. When patients have potassium loss, especially if the occurrence of hypokalemia is more harmful to patients (such as those who use digitalized rehmannia drugs), preventive supplement of potash should be required, such as eating little, severe or chronic diarrhea, long-term administration of adrenocortical hormone, potassium loss nephropathy, Bartter syndrome, etc.
3. Frequent, multi-source premature beats or rapid arrhythmia may be caused by digitalization poisoning.
Shijiazhuang No. 4 Pharmaceutical Co., Ltd., as one of the leading manufacturers in Chinese pharmaceutical industry and a well-known brand, has a business history of seventy years. The company principally specializes in R & D, manufacture and sales of wide types of drugs mainly including intravenous infusion.
The production lines have achieved full automation control and information control in the production process and logistics process and reached international advanced level by integrating the world's leading equipment and technology.
With product quality as its life, the Company always organizes production in strict accordance with GMP requirements, establishes and implements superior service concepts and measures and provides guarantee for the health of the majority of patients at home and abroad with excellent quality products and services.
The Company has a powerful R&D team and made a number of achievements in scientific research and undertaken many major scientific and technological innovation projects and industrialization projects by firmly grasping the pulse of pharmaceutical development, increasing new product development investment and accelerating the pace of technological innovation.
Large volume injection is the key products, tablets, capsules, small volume injection and other forms are manufactured also. Recently API has been put into production and sales. There are more than ten international advanced production lines for the large volume injection, its production scale, technology level, brand influence and economic benefit are on the forefront of domestic counterparts, and it has become one of China's top 100 pharmaceutical industry enterprises and China's top 10 chemical and pharmaceutical industry preparation export-oriented excellent enterprise brands for many consecutive years.
The products are radiated to all provinces, autonomous regions and municipalities in China and also exported to many overseas markets, including more than 80 countries in Asia, Americas, Europe, Oceania, Africa and other continents, and it has become one of the main export enterprises of infusion products.
){kind=link}